Article
HemoTypeSC, a low-cost point-of-care testing device for sickle cell disease: Promises and challenges.
Blood cells, molecules & diseases - 1 Sept 2019
Nnodu Obiageli, Isa Hezekiah, Nwegbu Maxwell, Ohiaeri Chinatu, Adegoke Samuel, Chianumba Reuben, Ugwu Ngozi, Brown Biobele, Olaniyi John, Okocha Emmanuel, Lawson Juliet, Hassan Abdul-Aziz, Diaku-Akinwumi Ijeoma, Madu Anazoeze, Ezenwosu Osita, Tanko Yohanna, Kangiwa Umar, Girei Ahmed, Israel-Aina Yetunde, Ladu Adama, Egbuzu Perpetua, Abjah Usman, Okolo Angela, Akbulut-Jeradi Nagihan, Fernandez Maria, Piel Frédéric B, Adekile Adekunle
Abstract excerpt
BACKGROUND: Sickle cell disease (SCD) is a neglected burden of growing importance. >312,000 births are affected annually by sickle cell anaemia (SCA). Early interventions such as newborn screening, penicillin prophylaxis and hydroxyurea can substantially reduce the mortality and morbidity associated with SCD. Nevertheless, their implementation in African countries has been mostly limited to pilot projects. Recent...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.